TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02645058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESWL
Description: Treatment by extracorporeal shock waves lithotripsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid and flexible ureteroscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithotripter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basket for fragment removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General or spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous pain medication
Description: If required by the patient
Study: NCT04410055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static standing
Description: We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic standing
Description: We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
Study: NCT02645058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-ray
Description: To focus the stone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-ray
Description: To focus the stone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: To focus the stone
Study: NCT06216015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will engage in combined training five times a week, with activities including 2 minutes of stationary marching and a set of 15 repetitions for squats, bilateral hip abduction, plantar flexion, floor abdominal exercises, and arm flexion with the knee close to the ground. Additionally, twice a week on non-consecutive days, volunteers partake in 20 minutes of aerobic walking.~The second program starts with a 2-minute stationary march, followed by 2 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion with knee support, floor abdominal exercises, and concludes with 30 minutes of aerobic exercise.~The third program starts with a 2-minute stationary march, followed by 3 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion, floor abdominal exercises, and includes thrice-weekly aerobic sessions lasting 30 minutes each.
Study: NCT01694823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-ACI
Description: Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）
Study: NCT03484611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
Study: NCT06216015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continue exercising
Description: Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue exercising
Description: Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
Study: NCT04435145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage warning label
Description: A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
Study: NCT03484611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
Study: NCT02746393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Advocates Program
Description: Provided services and support to address identified social needs from health advocate navigators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 211 Information Sheet
Description: Receive a printed list of community resources to address social needs.
Study: NCT03484611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: 0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: 0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: 0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: vaginal prontogest 400 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: vaginal prontogest 400 mg twice daily
Study: NCT00176631

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: licorice root extract
Description: Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
Study: NCT03221231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 1200 mg/day, twice daily, N-acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: twice daily, placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive measures

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neurocognitive measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-inflammatory measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro-inflammatory measures

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuro-inflammatory measures
Study: NCT02484313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatments
Description: commercially available food products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatments
Description: commercially available food products
Study: NCT04305379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented Bladder Neck Reconstruction
Description: Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bladder Neck Reconstruction
Description: Standard Bladder Neck Reconstruction with Intussusception Only
Study: NCT03484611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: vaginal prontogest 400 mg twice daily
Study: NCT01048931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port LAVH
Description: single-port LAVH
Study: NCT01276951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of cytokine production
Description: We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of cytokine production
Description: We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
Study: NCT04438889

Intervention type: OTHER
Intervention: Non-interventional
Description: Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.

Intervention type: OTHER
Intervention: Non-interventional
Description: Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.

Intervention type: OTHER
Intervention: Non-interventional
Description: Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.

Intervention type: OTHER
Intervention: Non-interventional
Description: Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
Study: NCT01929395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supine MRI
Description: A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supine MRI
Description: A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
Study: NCT03554252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequencies
Description: Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percentages
Description: Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
Study: NCT03736928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA dose level 1 or 2
Description: Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
Study: NCT03989219

Intervention type: PROCEDURE
Intervention: plasma cfDNA methylation
Description: plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
Study: NCT01276951

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Analysis of cytokine production
Description: We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
Study: NCT03616821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
Study: NCT02024893

Intervention type: OTHER
Intervention: Observational study
Description: Observation and type of data collected are listged in detail under 'description

Intervention type: OTHER
Intervention: Observational study
Description: Observation and type of data collected are listged in detail under 'description

Intervention type: OTHER
Intervention: Observational study
Description: Observation and type of data collected are listged in detail under 'description
Study: NCT03736928

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA dose 3
Description: Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA dose 4
Description: Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
Study: NCT04425889

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)
Description: a blood sample is drained for detection of IgG and IgM antibody
Study: NCT03928431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maternal microbiota
Description: See arm descriptions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maternal microbiota
Description: See arm descriptions
Study: NCT03265509

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glutamine supplementation
Description: 30 g/day glutamine supplementation for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fantomalt supplementation
Description: 30 g/day fantomalt supplementation for three months
Study: NCT01325480

Intervention type: DEVICE
Intervention: Cardiac Pacing
Study: NCT03301103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A
Description: After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
Study: NCT03169829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Diet
Description: Adapted from National Kidney Foundation guidelines for HD1~* Animal only Protein~* Refined only Grains~* Limit Dairy~* Low-k only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-k
Description: •¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~* Limit Dairy, provide Soymilk Dairy~* Low-k only Fruit and Vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard
Description: •¼ Animal, ¾ Plant Proteins~* Refined, ½ Whole Grain~  •Limit Dairy, provide Soymilk Dairy~* Low-k, Fruit and Vegetables~* High-k Fruit and Vegetables
Study: NCT03593967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARTISAN
Description: In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARTISAN
Description: In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share
Study: NCT02426554

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DDU-supplement
Description: DDU: Vitamin D, DHA, Uridine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Study: NCT00583323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomotil
Description: Orally 10ml of Lomotil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10 ml orally
Study: NCT04286542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cold, dry air
Description: Participants will be exposed to cold (\<-10°C, \<10% relative humidity), dry air for 15 minutes.
Study: NCT04362904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Study: NCT03301103

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: E. coli strain E1392-75-2A
Description: After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
Study: NCT00486538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: One oral dose daily.
Study: NCT03860545

Intervention type: DIAGNOSTIC_TEST
Intervention: urine and blood analysis
Description: concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively

Intervention type: DIAGNOSTIC_TEST
Intervention: urine and blood analysis
Description: concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively